Pharmaceutical Technology Europe - July 2010 - (Page 3)

Obstacles to implementing an effective anti-counterfeit strategy: can they be overcome? Pharmaceutical supply chains are global, but the regulatory environment for anti-counterfeiting is not. Fortunately, this is slowly changing with the FDA and the EU gearing up for new standards and legislation, but for global track-andtrace to become a reality, a clear international compliance framework based on open technology will be a critical first step. Enforcing track-and-trace fully throughout the supply chain, however, will be a problem because of the inherent difficulty of reading codes or checking the authentication features for every pack at every transaction. One hundred percent coverage is impractical with any anti-counterfeiting system, but serialisation is a good start and the wider the net the harder it is for counterfeiters to evade it. Companies just need to make sure they keep checking for holes. Is the pharma industry ready? Various false starts with different kinds of anti-counterfeiting technologies have led many companies to take a wait-and-see approach. Companies have invested to comply with national drug tracking regulations and have protected key products with targeted authentication initiatives, but many have not implemented serialisation across their entire product range. Most companies are now gearing up to do this, but will need to devote regular Board-level attention to anti-counterfeiting to develop and maintain momentum. A core, global, interoperable framework with optional additional layers of local flexibility is key to an anti-counterfeiting solution’s success. Ubiquitous technologies tend to be quite long-lived, so once 2D codes become the standard data carrier, we will be using them for a while. The open In the future, standards on which non-digital serialisation is built will authentication will also allow integration become ever more of other complementary important; codes can be technologies, such copied and RFID chips as RFID. Many other cloned, so we still need technologies, such as methods that can obtain on-dose technologies, are a definitive authentic/ also being developed, fake answer to the Mark Davison, and the worldwide rise question “Is this product Pharma Pieces of social networking and real?” PTE mobile telephony also holds interesting potential for the combination of authentication with marketing and customer interaction. Based on a contribution by Mark Davison, Managing Partner at Pharma Pieces. To read the full version of this article, go to 1 CONTENTS 8 EDIBLE MICROTAGS 3 OVERCOMING OBSTACLES 9 X-RAY ANALYSIS 4 EU LEGISLATION 11 RAMAN SPECTROSCOPY 6 DATA MATRIX CODES 14 TOP TECHNOLOGIES

Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - July 2010

Pharmaceutical Technology Europe - July 2010
Can Pharma Keep Pace with the Counterfeiters?
Obstacles to Implementing an Effective Anti-Counterfeit Strategy: Can They Be Overcome?
EU Anti-Counterfeiting Legislation on its Way
You Can't Control What You Can't Measure
Data Matrix Barcodes: Points to Consider
Authenticating Drugs with Edible Microtags
The Power of X-Ray Analysis
NIR Chemical Imaging Could Hold Key Data
How Raman Spectroscopy is Benefitting Developing and Developed Countries
Overt Versus Convert Technologies
Serialisation is Here to Stay
Eight Latest Technologies Showcased

Pharmaceutical Technology Europe - July 2010